Sumaxin Cleansing Pads

SUMAXIN CLEANSING PADS- sulfacetamide sodium and sulfur cloth
SUMAXIN CP- sulfacetamide sodium and sulfur
Medimetriks Pharmaceuticals, Inc.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

In a vehicle containing Green Tea & Aloe

Rx Only

DESCRIPTION

Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Chemically sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:

Chemical Structure
(click image for full-size original)

Each pad of Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads is coated with a cleanser-based formulation. Each gram of this cleanser-based formulation contains 100 mg of Sodium Sulfacetamide and 40 mg of Sulfur. The cleanser base consists of: aloe, butylated hydroxytoluene, cetyl alcohol, disodium oleamido MEA sulfosuccinate, edetate disodium, fragrance, glycerin, glyceryl stearate/PEG-100 stearate, green tea, methylparaben, propylparaben, purified water, sodium cocoyl isethionate, sodium lauryl sulfoacetate, sodium thiosulfate, stearyl alcohol.

CLINICAL PHARMACOLOGY

The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

INDICATIONS

Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS

Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads are contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads are not to be used by patients with kidney disease.

WARNINGS

Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.

FOR EXTERNAL USE ONLY. Keep away from eyes. Keep out of reach of children. Keep container tightly closed.

PRECAUTIONS

General

If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Information for Patients

Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.

Carcinogenesis, Mutagenesis and Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

PREGNANCY

Category C

Animal reproduction studies have not been conducted with Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads. It is also not known whether Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads should be given to a pregnant woman only if clearly needed.

NURSING MOTHERS

It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads are administered to a nursing woman.

PEDIATRIC USE

Safety and effectiveness in children under the age of 12 have not been established.

Adverse Reactions to Sumaxin Cleansing Pads

Although rare, sodium sulfacetamide may cause local irritation.

DOSAGE AND ADMINISTRATION

Wash affected area(s) with cleansing pad once or twice daily, or as directed by your physician. Wet area(s) with water. Wet pad with a little water and work into a full lather. Cleanse area(s) with pad for 10-20 seconds, avoiding eyes. Rinse thoroughly and pat dry. Discard pad. Do not flush.

HOW SUPPLIED

Sumaxin® (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads are available in boxes of 60 cloths (3.7 g), NDC 43538-100-60.

Store at 15°-30° C (59°-86° F).

To report SUSPECTED ADVERSE REACTIONS , contact Medimetriks Pharmaceuticals, Inc., at 1-973-882-7512 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Manufactured for:
MEDIMETRIKS
PHARMACEUTICALS, INC.

383 Route 46 West
Fairfield, NJ 07004-2402 USA

www.medimetriks.com

IP001-R5
Rev. 10/17

PRINCIPAL DISPLAY PANEL — 60 Pad Carton

NDC 43538-100-60

Rx Only
sumaxin®
(sodium sulfacetamide 10% & sulfur 4%)
Cleansing Pads

In a vehicle containing Green Tea & Aloe

60 Cleansing Pads
Net wt. 3.7 g Each

MEDIMETRIKS PHARMACEUTICALS, INC.

PRINCIPAL DISPLAY PANEL -- 60 Pad Carton
(click image for full-size original)

PRINCIPAL DISPLAY PANEL — Kit Carton

NDC 43538-101-60

Rx Only
sumaxin®

(Sodium Sulfacetamide 10%
& Sulfur 4%) Cleansing Pads
CP
KIT

CONTENTS:

1 –
Sumaxin® (Sodium Sulfacemide 10% & Sulfur 4%)
Cleansing Pads Carton — 60 Pads (Net wt. 3.7 g each)
1 –
Rehyla® Wash Moisturizing Daily Wash (16 fl. oz.)

MEDIMETRIKS PHARMACEUTICALS, INC.

PRINCIPAL DISPLAY PANEL -- Kit Carton
(click image for full-size original)
Established Pharmacological Class
Substance Pharmacological Class
Rehyla Wash Cleansing (cold creams, cleansing lotions, liquids, and pads)
SUMAXIN CLEANSING PADS sulfacetamide sodium and sulfur cloth
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43538-100
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Sulfacetamide sodium (sulfacetamide) Sulfacetamide sodium 100 mg in 1 g
Sulfur (sulfur) Sulfur 40 mg in 1 g
Inactive Ingredients
Ingredient Name Strength
aloe
butylated hydroxytoluene
cetyl alcohol
disodium oleamido monoethanolamine sulfosuccinate
edetate disodium
glycerin
green tea leaf
methylparaben
propylparaben
water
sodium cocoyl isethionate
sodium lauryl sulfoacetate
sodium thiosulfate
stearyl alcohol
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:43538-100-60 60 PACKET in 1 CARTON contains a PACKET
1 3.7 g in 1 PACKET This package is contained within the CARTON (43538-100-60)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
UNAPPROVED DRUG OTHER 01/01/2009
SUMAXIN CP sulfacetamide sodium and sulfur kit
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43538-101
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:43538-101-60 1 KIT in 1 CARTON None
Quantity of Parts
Part # Package Quantity Total Product Quantity
Part 1 60 PACKET 222 g
Part 2 1 BOTTLE, PUMP 454 g
Part 1 of 2
SUMAXIN CLEANSING PADS sulfacetamide sodium and sulfur cloth
Product Information
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
sulfacetamide sodium (sulfacetamide) sulfacetamide sodium 100 mg in 1 g
sulfur (sulfur) sulfur 40 mg in 1 g
Inactive Ingredients
Ingredient Name Strength
aloe
butylated hydroxytoluene
cetyl alcohol
disodium oleamido monoethanolamine sulfosuccinate
edetate disodium
glycerin
green tea leaf
methylparaben
propylparaben
water
sodium cocoyl isethionate
sodium lauryl sulfoacetate
sodium thiosulfate
stearyl alcohol
Packaging
# Item Code Package Description Multilevel Packaging
1 60 PACKET in 1 CARTON contains a PACKET
1 3.7 g in 1 PACKET This package is contained within the CARTON
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 01/01/2009
Part 2 of 2
REHYLA WASH inert
Product Information
Route of Administration TOPICAL DEA Schedule
Ingredients
Ingredient Name Quantity
water
glyceryl monostearate
glycerin
cetyl alcohol
disodium oleamido mipa-sulfosuccinate
cholesterol
disodium laureth sulfosuccinate
helianthus annuus seed wax
caprylyl glycol
propylene glycol
phenoxyethanol
sodium cocoyl isethionate
cocamidopropyl betaine
sodium methyl cocoyl taurate
C13-14 isoparaffin
sodium chloride
niacinamide
edetate disodium
hexylene glycol
laureth-7
chamaemelum nobile flower
hyaluronate sodium
Packaging
# Item Code Package Description Multilevel Packaging
1 1 BOTTLE, PUMP in 1 CARTON contains a BOTTLE, PUMP
1 454 g in 1 BOTTLE, PUMP This package is contained within the CARTON
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Cosmetic 08/01/2011
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
Unapproved drug other 08/01/2011
Labeler — Medimetriks Pharmaceuticals, Inc. (019903816)
Establishment
Name Address ID/FEI Operations
IGI Laboratories 011036910 MANUFACTURE (43538-100), MANUFACTURE (43538-101)

Revised: 12/2017 Medimetriks Pharmaceuticals, Inc.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.